- ICH GCP
- Registre des essais cliniques de l'UE
Derniers essais
EudraCT Number: 2022-002214-17 | Sponsor Protocol Number: NL78220.029.21 | Start Date: 2023-04-24 | ||||||||||||||||
Sponsor Name: Amsterdam University Medical Centers | ||||||||||||||||||
Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial | ||||||||||||||||||
Medical condition: Recurrent colorectal liver metastases | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001413-37 | Sponsor Protocol Number: BELI(E)VE-Trial | Start Date: 2023-04-24 | |||||||||||
Sponsor Name: University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial | |||||||||||||
Medical condition: relapsed and refractory t(11;14) Multiple Myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003063-10 | Sponsor Protocol Number: ARGX-113-2010 | Start Date: 2023-04-21 | |||||||||||
Sponsor Name: argenx BV | |||||||||||||
Full Title: An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid | |||||||||||||
Medical condition: Bullous Pemphigoid | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Ongoing) GR (Ongoing) HU (Ongoing) DE (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) NL (Ongoing) HR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-004155-13 | Sponsor Protocol Number: BMS_IM101-931 | Start Date: 2023-04-20 | |||||||||||
Sponsor Name: Universitätsklinikum Freiburg | |||||||||||||
Full Title: Study to investigate the restoring of an immunological balance during therapy with abatacept Abatacept restores immune system equilibrium (ARISE) | |||||||||||||
Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-006664-24 | Sponsor Protocol Number: INVEX-CLIN-IIH-301 | Start Date: 2023-04-20 | |||||||||||
Sponsor Name: Invex Therapeutics Ltd. | |||||||||||||
Full Title: A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension | |||||||||||||
Medical condition: Idiopathic intracranial hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004244-28 | Sponsor Protocol Number: BAN2401-G000-303 | Start Date: 2023-04-17 | |||||||||||
Sponsor Name: Eisai Ltd. | |||||||||||||
Full Title: AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Dise... | |||||||||||||
Medical condition: Preclinical Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001175-14 | Sponsor Protocol Number: BHV3000-406 | Start Date: 2023-04-17 | |||||||||||
Sponsor Name: Biohaven Pharmaceuticals, Inc. | |||||||||||||
Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use | |||||||||||||
Medical condition: migraine attacks with or without aura | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) IT (Ongoing) SE (Ongoing) FI (Ongoing) DK (Ongoing) AT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001876-32 | Sponsor Protocol Number: SLN360-002 | Start Date: 2023-04-14 | ||||||||||||||||
Sponsor Name: Silence Therapeutics plc | ||||||||||||||||||
Full Title: A multi-centre, randomised, double-blind placebo-controlled, Phase 2 study to investigate efficacy, safety and tolerability of SLN360 in participants with elevated lipoprotein(a) at high risk of at... | ||||||||||||||||||
Medical condition: elevated lipoprotein (a) and high risk of atherosclerotic cardiovascular disease (ASCVD) events | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) NL (Ongoing) SK (Ongoing) DK (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000788-30 | Sponsor Protocol Number: 1.2022 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Uzdrowisko Kamień Pomorski S.A. | ||||||||
Full Title: Evaluation of the effectiveness of Methocarbamol in the treatment of spasticity in people with spinal cord injury. | ||||||||
Medical condition: | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: PL (Ongoing) | ||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001181-10 | Sponsor Protocol Number: P003077 | Start Date: 2023-04-13 | ||||||
Sponsor Name: Medical Center - University of Freiburg | ||||||||
Full Title: Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line treatment in elderly primary CNS lymphoma patients – a rand... | ||||||||
Medical condition: Primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is a rare lymphoma affecting only the central nervous system compartment. PCNSL patients are typically 60 years or older ... | ||||||||
|
||||||||
Population Age: Elderly | Gender: Male, Female | |||||||
Trial protocol: AT (Ongoing) | ||||||||
Trial results: (No results available) |